After Hours
$
100.93
Change
-0.06 -0.06%
Volume
Volume 3,233
Jan 15, 2021, 7:22 p.m.
Quotes are delayed by 20 min
Previous close
$ 102.51
$ 100.99
Change
-1.52 -1.48%
Day low
Day high
$100.57
$103.00

52 week low
52 week high
$43.29
$125.61

Market cap
$5.63B
Average volume
510,563
P/E ratio
18.59
Rev. per Employee
$173,661
EPS
5.43
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on BPMC
-
Blueprint Medicines started at hold with $110 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
Here Are Stocks That Benefit Under Different Election Outcomes
- Barron's Online
-
Charting a bullish reversal, S&P 500 spikes to challenge 50-day average
- Michael Ashbaugh
-
The Pandemic Speeds Up the Health-Care Revolution
- Barron's Online
-
Roche, Blueprint to co-develop lung-cancer drug
- MarketWatch.com
-
7 Biotech Stocks to Buy for a Post-Pandemic World
- Barron's Online
-
Blueprint Medicines upgraded to outperform at BMO Capital
- Tomi Kilgore
-
Blueprint Medicines upgraded to buy from hold at Deutsche Bank
- Tomi Kilgore
-
Blueprint Medicines started at market perform at BMO Capital
- Tomi Kilgore
-
A Biotech Veteran Thinks He Can Undersell the Entire Drug Industry
- Barron's Online
-
Blueprint Medicines reiterated as buy at Canaccord
- Ciara Linnane
-
Blueprint Medicines upgraded to strong buy from outperform at Raymond James
- Tomi Kilgore
-
Blueprint Medicines started at buy with $110 stock price target at Deutsche Bank
- Tomi Kilgore
-
Charting a bull-trend pullback, S&P 500 nails major support
- Michael Ashbaugh
-
Blueprint Medicines started at overweight with $112 stock price target at Morgan Stanley
- Tomi Kilgore
-
Cancer Stocks Are Heating Up After the Third Big Merger in a Month
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Deciphera Pharma Scores A Sell-Side Recommendation
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For March 13, 2017
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For February 15, 2017
- Benzinga.com
Other News on BPMC
-
Blueprint Medicines (BPMC) Received its Third Buy in a Row
- SmarterAnalyst
-
Blueprint Medicines announces leadership transitions
- Seeking Alpha
-
Amarin (AMRN) Surges: Stock Moves 9% Higher
- Zacks.com
-
Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
- Seeking Alpha
-
A Director at Blueprint Medicines is Exercising Options
- SmarterAnalyst
- Loading more headlines...
Press Releases on BPMC
-
Blueprint Medicines Announces R&D Leadership Transitions
- PR Newswire - PRF
-
Blueprint Medicines Reports Third Quarter 2020 Financial Results
- PR Newswire - PRF
-
Blueprint Medicines Corp. to Host Earnings Call
- ACCESSWIRE
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com